We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.
Issue 29 Synovium (Spring 2010)
There is always the concern with powerful immunosuppressive treatments that the short-term benefit might be at the price of increased long-term risk of malignant disease. So it is comforting to read that in a Swedish study following 6366 patients with rheumatoid arthritis treated with the anti-TNF drugs infliximab, adalimumab and etanercept1 no increased risk of cancer was observed in 6 years of follow-up compared with patients on other therapies or not taking medication. Six years is not long in the timeline of a disease like rheumatoid arthritis and clearly much longer observation is needed, but this is encouraging information for patients.